Copy
View this email in your browser
November 17, 2021

COVID-19 Vaccine Market Dashboard

Find below an overview of the latest COVID-19 vaccine news, reflected in UNICEF’s COVID-19 Vaccine Market Dashboard.
Key highlights
As of November 15, 2021: 
 
  • An estimated 8.4 Billion COVID-19 vaccine doses have been delivered worldwide to 207 countries/territories [+600 Million or +7,7%]*. Out of these:
    • Over 486 Million doses were delivered to 144 countries/territories through the COVAX Facility [+60 Million or +14,1%]*, and
    • Over 15.6 Million doses were delivered through AVAT, the African Vaccine Acquisition Trust to 36 countries/territories [+4,8 Million or +44,4%]*.
  • Over 433 Million donated and faciliated doses have been delivered worldwide [+73 Million or +20,3%]*. Out of these:
    • 162 Million vaccine doses have been donated through COVAX [+12 Million or +8%]*
      • The most donated vaccines through COVAX are: AstraZeneca (44%), Moderna (34%), Janssen (18%) and Pfizer BioNTech (4%).
    • Over 101 Million delivered doses were facilitated by the USA, meaning that they were cost-shared between donor and the COVAX Facility [+33 Million or +48,5%]*.
    • 170 Million doses have been donated outside of COVAX [+28 Million or +19,7%]*, the top 5 donors being:
                                   
  • Of the publicly  reported prices for COVID-19 vaccines, the average price is $12.5 per dose with high variability across products, suppliers and buyers. This is not considering the prices reported for private markets.

* Numbers in [brackets] refer to changes since the previous issue of the Newsletter from October 28, 2021. 
Key Insights
  • While global vaccine deliveries up to date are sufficient to vaccinate over 50% of the world's population, a highly unequal vaccine distribution has meant that 81 countries (mostly LICs and LMICs) have so far not received sufficient vaccine doses to vaccinate 40% of their population - a global target set by WHO to be met by end of 2021 (table 1). 
  • Deliveries to LICs and LMICs (excl. India) have increased considerably in the past months after seeing a hike of 240% between June and July (graph 1). Deliveries through COVAX have since averaged 51 Million doses monthly, compared to 8 Million between February and June. 
    • However, with total deliveries currently standing at merely 864 Million doses, a significant gap will need to be closed for countries to reach the 40% target by end of this year.
  • Only 13 LMICs have thus far obtained enough vaccines to cover 40% of their population (graph 2). On the opposite spectrum are 23 countries that have still not received enough vaccine doses to surpass the 10% target that was set to be achieved worldwide by September this year, 10 of which are located in Sub-Saharan Africa.

Note: This table displays the amount of doses delivered to countries (as of 10.11.2021) grouped by WB Income Status, the number of vaccine courses delivered as a percentage of population, the number of countries in each income group, as well as the number of countries that have not received enough doses to vaccinate 70% and 40% of the population respectively. The calculation on deliveries as a percentage of population is based on the actual number of doses in a full course of a given vaccine but does not account for country-level vaccination strategies (i.e. whether countries prioritize first dose roll-out or full course) nor for potential booster shots. Only countries with population data could be considered in this table. 


Note: This graph displays the deliveries to LICs and LMICs over time (as of 10.11.2021) by supply source (mechanism). The line chart illustrates the cumulative deliveries. India has been excluded due to the country's high share of deliveries. October deliveries are likely to be incomplete due to a time-lag in the media monitoring process. 




   



Note: This bar chart displays the number of vaccine courses that have been delivered (not necessarily administered) to a country as a percentage of its population. The calculation is based on the actual number of doses required for a full course of a given vaccine but does not account for country-level vaccination strategy (i.e. whether countries prioritize first dose roll-out or full course) nor for potential booster shots. The estimated population coverage is presented against WHO's 40% target set to be achieved globally by the end of this year. Deliveries are shown by supply source (mechanism).
 
What's New in the Dashboard?
Manufacturing Agreements - Production Location


A new map on the production location of manufacturers has been added to the capacity tab in the dashboard. This visualisation uses the agreements reached between vaccine developers and manufacturers as a basis and provides a detailed view on the different production locations, as well as on the different types of production of each vaccine. The types of productions observed in manufacturers include "End-to-end" productions; "Fill-and-Finish" processes; Drug substance manufacturing; Adjuvant manufacturing; as well as Excipient suppliers. The visualisation allows to filter by vaccine, as well as by production type.
Market Updates
COVID-19 vaccine country approvals

Between October 18 - November 10, four different vaccines have been authorized for emergency use in two countries, one of which has been authorized for the first time (KconecaVac):
Country Vaccine Name Vaccine Developer  Status Source
Indonesia Covovax Novavax Emergency Use Novavax
Indonesia KconecaVac Biokangtai (Beijing Minhai) Emergency Use Barrons
Cambodia Sputnik Light Gamaleya Research Institute Emergency Use RDIF
Cambodia Sputnik V Gamaleya Research Institute Emergency Use RDIF

Find an overview of all country approvals in the "Products" section of the dashboard at this link.

COVID-19 vaccine agreements

Vaccine developers have entered into supply agreements for a total of 20.4 Billion doses globally. Between October 18 - November 10, the following new agreements were signed between countries and vaccine developers:
Country/
territory
Vaccine Developer  Vaccine Name Secured Doses Source
Belarus Sinopharm BBIBP-CorV 1 Million Belta
Costa Rica Pfizer/BioNTech Comirnaty 3.5 Million Efe
African Union Moderna mRNA-1273 110 Million Moderna
COVAX AMC Moderna mRNA-1273 116.6 Million Moderna
USA Pfizer/BioNTech Comirnaty 50 Million Pfizer
Brazil AstraZeneca AZD1222 60 Million AB
India Zydus Cadila ZyCov-D    20 Million Mint
India Bharat Biotech Covaxin 60 Million Mint
India AstraZeneca Covishield 220 Million Mint
Iran Organization of Defensive Innovation and Research FAKHRAVAC 3 Million  NYT
Canada  Pfizer/BioNTech Comirnaty 2.9 Million Reuters
Philippines  EuBiologics EuCorVac-19 40 Million PHEmb

Find an overview of COVID-19 vaccine supply agreements under the "Agreements" section of the dashboard at this link.
Reported COVID-19 vaccine donations

More than 433 Million donated and facilitated doses have been delivered globally, out of which:
  • 162 Million doses have been donated through the COVAX Facility,
  • 101 Million doses were facilitated through the COVAX Facility, and
  • 170 Million doses were donated through private, bilateral and other multilateral channels.

Between October 18 - November 10, over 16.9 Million doses have been donated through COVAX:
Donor Region Mechanism Vaccine Donated Doses
USA Sub-Saharan Africa COVAX Janssen 3,528,500
USA Latin America and the Caribbean COVAX Pfizer/BioNTech 500,760
USA Latin America and the Caribbean COVAX Moderna 250,040
Switzerland Sub-Saharan Africa COVAX AstraZeneca 105,600
Switzerland South Asia COVAX AstraZeneca 165,600
Switzerland Middle East and North Africa COVAX AstraZeneca 24,000
Sweden South Asia COVAX AstraZeneca 226,800
Sweden Sub-Saharan Africa COVAX AstraZeneca 165,600
Sweden Middle East and North Africa COVAX AstraZeneca 115,200
Spain Sub-Saharan Africa COVAX AstraZeneca 326,400
Spain Latin America and the Caribbean COVAX AstraZeneca 1,207,110
Norway Sub-Saharan Africa COVAX AstraZeneca 343,800
Norway South Asia COVAX AstraZeneca 100,800
New Zealand East Asia and Pacific COVAX AstraZeneca 708,400
Italy Middle East and North Africa COVAX AstraZeneca 1,139,600
Italy Sub-Saharan Africa     COVAX AstraZeneca 165,900
Iceland Sub-Saharan Africa   COVAX AstraZeneca 12,000
Germany East Asia and Pacific COVAX AstraZeneca 793,900
Germany Middle East and North Africa COVAX AstraZeneca 406,400
Germany Sub-Saharan Africa  COVAX AstraZeneca 750,500
Germany South Asia COVAX AstraZeneca 1,021,800
France Sub-Saharan Africa COVAX AstraZeneca 2,317,500
Denmark Sub-Saharan Africa COVAX AstraZeneca 192,000
Canada Sub-Saharan Africa COVAX AstraZeneca 326,400
Canada Middle East and North Africa COVAX Moderna 784,280
Canada Latin America and the Caribbean COVAX AstraZeneca 696,000
Belgium Sub-Saharan Africa COVAX AstraZeneca 527,460
Between October 18 - November 10, over 31 Million doses have been facilitated through COVAX, meaning that they were cost-shared between donors and the COVAX Facility. These include the following delivered doses: 
 
Donor Recipient (UNICEF Region) Mechanism Vaccine Donated Doses
USA East Asia and Pacific COVAX Pfizer/BioNTech 7,366,320
USA Europe and Central Asia COVAX Pfizer/BioNTech 800,280
USA Latin America and the Caribbean COVAX Pfizer/BioNTech 421,200
USA Middle East and North Africa COVAX Pfizer/BioNTech  5,882,760
USA South Asia COVAX Pfizer/BioNTech 8,570,250
USA Sub-Saharan Africa COVAX Pfizer/BioNTech 7,757,100
Between October 18 - November 10, over 17 Million doses have been donated bilaterally and privately. These include the following donation flows: 
 
Donor Recipient Mechanism Vaccine Donated Doses Source
China Uganda Bilateral Sinovac 700,000 AA
China Philippines Bilateral Sinovac 1 Million MB
China Bangladesh Bilateral Sinopharm 200,000 CHEmb
China Ethiopia Bilateral Sinopharm 800,000 CD
China Bangladesh Bilateral Sinovac 1 Million TI
China Tanzania Bilateral Sinopharm 500,000 NCN
China Egypt Bilateral Sinovac 2 Milion ET
USA Mexico Bilateral AstraZeneca 3.4 Million USE/DR
USA Taiwan Bilateral Moderna 1.5 Million FT
Dominican Rep. Costa Rica Bilateral AstraZeneca 56,800 TT
Turkey Montenegro Bilateral Sinovac 100,000 GovME
AstraZeneca Viet Nam Viet Nam Private AstraZeneca 386,400 VN
Japan Viet Nam Bilateral AstraZeneca 500,000 VN
Japan Indonesia Bilateral AstraZeneca 224,000 AN
Japan Philippines Bilateral AstraZeneca 896,000 PS
Japan Philippines Bilateral AstraZeneca 1.1 Million GM
Japan Taiwan Bilateral AstraZeneca 300,000 GovTW
Brunei Philippines Bilateral AstraZeneca 2,000 SS
International Red Crescent Society Bangladesh Bilateral Sinovac 200,000 DB
Netherlands Indonesia Bilateral Moderna 819,600 Tempo
Australia Viet Nam Bilateral AstraZeneca 800,000 VNE
Cambodia Viet Nam  Bilateral Sinopharm 200,000 KT
Hungary Egypt Bilateral AstraZeneca 250,000 Zewya
Poland Serbia Bilateral AstraZeneca 200,000 GovRS

Go to the "Deliveries" section of the  dashboard at this link, to find an overview of COVID-19 vaccine donated.
Reported COVID-19 vaccine production capacity
  • Pfizer/BioNTech announced they will increase their production volume to  4 Billion doses annually in 2022 (Yahoo)
  • The Russian sovereign fund RDIF and South Korea's GL Rapha have announced they will produce more than 150 Million doses per year of Sputnik V (Reuters)
  • The Serum Institute of India (SII) has increased its monthly capacity of AstraZeneca vaccine doses to  240 Million doses (Reuters)
Find out more information on the reported global production capacity for the COVID-19 vaccine under the "Capacity" section of the dashboard at this link.
COVID-19 vaccine pipeline

A total of 27 vaccines have been approved for use by at least one National Regulatory Authority. 3 vaccines candidates are currently under regulatory review and 13 candidates are at Phase III clinical trials. On  November 3,  WHO issued its Emergency Use Listing for the eighth COVID-19 vaccine, namely for COVAXIN developed by Bharat Biotech. Since October 18, one additional vaccine received the Emergency Use Authorization for the first time. The following additional developments were reported:
Vaccine Name Vaccine Developer  Trial Stage Source
Covaxin Bharat Biotech WHO Emergency Use Listing WHO
KCONECAVAC Biokangtai (Beijing Minhai) Emergency Use Authorization Barrons
ReCOV Jiangsu RecBio Enters Phase II/III CT
Recombinant SARS-CoV-2 vaccine UMN Pharma (Shionogi) Enters Phase II/III Shionogi
Virus-like particles based oral vaccine Oravax Enters Phase I Oramed
DNA Vaccine University of Hong Kong Enters Phase I CT
Uvax-2129 Uvax Bio Preclinical BW
mRNA Vaccine against Delta Variant Ainos Inc Discovery AW

Go to the "Product" section of the dashboard at this link, to find an overview of COVID-19 vaccine pipeline.
Share Share
Tweet Tweet
Share Share
Go to the COVID-19 Vaccine Market Dashboard
Subscribe to our Newsletter
Access previous issues of the Newsletter
Copyright © 2021 UNICEF, All rights reserved.
You are receiving this email because you signed up for this Newsletter at UNICEF's website.

Our mailing address is:
UNICEF Supply Division
Oceanvej 10-12,
2150, Copenhagen
Denmark

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.